Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease
IntroductionThe commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrate...
Saved in:
| Published in | Gut Vol. 60; no. 7; pp. 923 - 929 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BMJ Publishing Group Ltd and British Society of Gastroenterology
01.07.2011
BMJ Publishing Group BMJ Publishing Group LTD |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0017-5749 1468-3288 1468-3288 |
| DOI | 10.1136/gut.2010.232025 |
Cover
| Abstract | IntroductionThe commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.Aims and methodsTo assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥70 points) in the intention-to-treat (ITT) population.Results103 patients were randomised to receive FOS (n=54) or placebo (n=49). More patients receiving FOS (14 (26%) vs 4 (8%); p=0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p=0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p<0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention.ConclusionAn adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. |
|---|---|
| AbstractList | The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.
To assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥ 70 points) in the intention-to-treat (ITT) population.
103 patients were randomised to receive FOS (n = 54) or placebo (n = 49). More patients receiving FOS (14 (26%) vs 4 (8%); p = 0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p = 0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p < 0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention.
An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.INTRODUCTIONThe commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.To assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥ 70 points) in the intention-to-treat (ITT) population.AIMS AND METHODSTo assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥ 70 points) in the intention-to-treat (ITT) population.103 patients were randomised to receive FOS (n = 54) or placebo (n = 49). More patients receiving FOS (14 (26%) vs 4 (8%); p = 0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p = 0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p < 0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention.RESULTS103 patients were randomised to receive FOS (n = 54) or placebo (n = 49). More patients receiving FOS (14 (26%) vs 4 (8%); p = 0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p = 0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p < 0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention.An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530.CONCLUSIONAn adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. IntroductionThe commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.Aims and methodsTo assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥70 points) in the intention-to-treat (ITT) population.Results103 patients were randomised to receive FOS (n=54) or placebo (n=49). More patients receiving FOS (14 (26%) vs 4 (8%); p=0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p=0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p<0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention.ConclusionAn adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. INTRODUCTION: The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease. AIMS AND METHODS: To assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of greater than or equal to 70 points) in the intention-to-treat (ITT) population. RESULTS: 103 patients were randomised to receive FOS (n=54) or placebo (n=49). More patients receiving FOS (14 (26%) vs 4 (8%); p=0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p=0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p<0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention. CONCLUSION: An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. Introduction The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease. Aims and methods To assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥70 points) in the intention-to-treat (ITT) population. Results 103 patients were randomised to receive FOS (n=54) or placebo (n=49). More patients receiving FOS (14 (26%) vs 4 (8%); p=0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p=0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (p<0.05) but no change in IL-12p40 production. There were no significant differences in the faecal concentration of bifidobacteria and F prausnitzii between the groups at baseline or after the 4-week intervention. Conclusion An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530. |
| Author | Benjamin, Jane L Ng, Siew C Stagg, Andrew J Kamm, Michael A Sanderson, Jeremy D McCarthy, Neil E Hart, Ailsa L Lindsay, James O Koutsoumpas, Andreas Whelan, Kevin Forbes, Alastair Hedin, Charlotte R H Knight, Stella C |
| Author_xml | – sequence: 1 givenname: Jane L surname: Benjamin fullname: Benjamin, Jane L organization: Nutritional Sciences Division, King's College London, London, UK – sequence: 2 givenname: Charlotte R H surname: Hedin fullname: Hedin, Charlotte R H organization: Nutritional Sciences Division, King's College London, London, UK – sequence: 3 givenname: Andreas surname: Koutsoumpas fullname: Koutsoumpas, Andreas organization: Nutritional Sciences Division, King's College London, London, UK – sequence: 4 givenname: Siew C surname: Ng fullname: Ng, Siew C organization: Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong – sequence: 5 givenname: Neil E surname: McCarthy fullname: McCarthy, Neil E organization: Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK – sequence: 6 givenname: Ailsa L surname: Hart fullname: Hart, Ailsa L organization: Antigen Presenting Research Group, Imperial College, London, UK – sequence: 7 givenname: Michael A surname: Kamm fullname: Kamm, Michael A organization: Departments of Medicine and Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, Australia – sequence: 8 givenname: Jeremy D surname: Sanderson fullname: Sanderson, Jeremy D organization: Nutritional Sciences Division, King's College London, London, UK – sequence: 9 givenname: Stella C surname: Knight fullname: Knight, Stella C organization: Antigen Presenting Research Group, Imperial College, London, UK – sequence: 10 givenname: Alastair surname: Forbes fullname: Forbes, Alastair organization: Centre for Gastroenterology and Nutrition, University College, London, UK – sequence: 11 givenname: Andrew J surname: Stagg fullname: Stagg, Andrew J organization: Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK – sequence: 12 givenname: Kevin surname: Whelan fullname: Whelan, Kevin organization: Nutritional Sciences Division, King's College London, London, UK – sequence: 13 givenname: James O surname: Lindsay fullname: Lindsay, James O email: james.lindsay@bartsandthelondon.nhs.uk organization: Digestive Diseases Clinical Academic Unit, Barts and the London NHS Trust, London, UK |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24228456$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21262918$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1rFDEUhoNU7LZ67Z0MSKmo0-ZjMpO5tItWoSiIH-BNOPmYbdbsZE1mqv33Zpm1CwWrV-HA876cPOcA7fWhtwg9JviEEFafLsbhhOI8UUYx5ffQjFS1KBkVYg_NMCZNyZuq3UcHKS0xxkK05AHap4TWtCVihhYfoTdh5ZI1LwsTRuVtqbzr87T2oK0KpQ79EIP31hRDdOCL0BVdHPUQyuDdIiTQ-hKiMzYVri9AD-7KFvMYLvvjVJhcDck-RPc78Mk-2r6H6POb15_mb8uLD-fv5q8uSsVZM5QKKGPCctVVRpDWVIIa2hhVi7YTbWWUYSQDnVGakaYVigPjXQ0KDNMCAztEeOod-zVc_wTv5Tq6FcRrSbDcOJPZmdw4k5OzHDmeIusYfow2DTLr0NZ76G0YkxQNyebqBmfy2Z0kaTirasyqTenTW-gyjLHPX89U0zKOKywy9WRLjWplzc2qf-6TgaMtAEmD7yL02qUdV1EqKl5njk-cjiGlaDup3QCD25wOnL_j76e3cv-2VU4Jlwb76waH-F3WDWu4fP9lLs_YN0a-njO52ez5xKvV8j_KX-zgnbC_0L8BBDvpDA |
| CODEN | GUTTAK |
| CitedBy_id | crossref_primary_10_1016_j_copbio_2016_11_011 crossref_primary_10_1093_ibd_izae115 crossref_primary_10_1093_ecco_jcc_jjz208 crossref_primary_10_14309_ajg_0000000000002578 crossref_primary_10_1016_j_jff_2020_104197 crossref_primary_10_1007_s00284_024_03997_y crossref_primary_10_1038_nrgastro_2016_141 crossref_primary_10_3389_fnut_2021_733433 crossref_primary_10_1017_neu_2017_3 crossref_primary_10_1016_j_ijbiomac_2024_132362 crossref_primary_10_3390_nu12103204 crossref_primary_10_1186_1471_230X_13_131 crossref_primary_10_1093_nutrit_nuab115 crossref_primary_10_1108_NFS_07_2017_0156 crossref_primary_10_3233_MNM_17182 crossref_primary_10_1017_S0029665120006953 crossref_primary_10_1007_s11899_016_0302_9 crossref_primary_10_1159_000367821 crossref_primary_10_3390_nu12061706 crossref_primary_10_1016_j_ijbiomac_2023_128835 crossref_primary_10_3390_microorganisms8111638 crossref_primary_10_3945_an_112_003046 crossref_primary_10_1111_apt_12500 crossref_primary_10_1017_S0029665113001262 crossref_primary_10_1038_srep17651 crossref_primary_10_3390_diagnostics11061090 crossref_primary_10_3390_foods8030092 crossref_primary_10_3390_nu15051080 crossref_primary_10_1016_j_jbiotec_2022_06_004 crossref_primary_10_3390_nu12072156 crossref_primary_10_1016_j_ijbiomac_2023_129131 crossref_primary_10_1007_s00281_025_01036_x crossref_primary_10_3389_fmicb_2016_01081 crossref_primary_10_1016_j_tim_2017_06_006 crossref_primary_10_1002_mnfr_201600129 crossref_primary_10_1111_jhn_12176 crossref_primary_10_2174_1381612826666200211121916 crossref_primary_10_1016_j_biopha_2021_112414 crossref_primary_10_1111_imm_12939 crossref_primary_10_3390_nu11071565 crossref_primary_10_1016_j_jinf_2018_10_005 crossref_primary_10_1097_MIB_0000000000000364 crossref_primary_10_3390_ijms17060919 crossref_primary_10_1016_j_autrev_2019_03_006 crossref_primary_10_1017_S0007114511007203 crossref_primary_10_1136_gutjnl_2014_308896 crossref_primary_10_1016_j_bcdf_2023_100375 crossref_primary_10_4110_in_2022_22_e44 crossref_primary_10_2174_1389201021666200107113812 crossref_primary_10_1111_apt_12404 crossref_primary_10_1038_nrgastro_2015_11 crossref_primary_10_1097_MPG_0000000000001896 crossref_primary_10_1097_SHK_0000000000001180 crossref_primary_10_5217_ir_2019_00078 crossref_primary_10_3390_foods11071044 crossref_primary_10_3748_wjg_v20_i33_11505 crossref_primary_10_1016_j_anaerobe_2017_01_001 crossref_primary_10_1128_mSphere_00771_19 crossref_primary_10_12998_wjcc_v11_i1_47 crossref_primary_10_3390_nu13072125 crossref_primary_10_1093_ecco_jcc_jjx109 crossref_primary_10_1017_S0007114514001275 crossref_primary_10_3390_nu15010162 crossref_primary_10_3920_QAS2015_0791 crossref_primary_10_1111_apt_13248 crossref_primary_10_12688_f1000research_9699_1 crossref_primary_10_3389_fmed_2022_887044 crossref_primary_10_12688_f1000research_9699_2 crossref_primary_10_1053_j_scrs_2017_09_005 crossref_primary_10_12688_f1000research_20805_1 crossref_primary_10_3389_fimmu_2017_00400 crossref_primary_10_1097_SGA_0000000000000047 crossref_primary_10_1093_ilar_ilv030 crossref_primary_10_1111_jgh_13695 crossref_primary_10_1155_2013_435268 crossref_primary_10_1007_s00203_022_03069_4 crossref_primary_10_1016_j_fochx_2024_101118 crossref_primary_10_3389_fimmu_2017_00417 crossref_primary_10_1016_j_psyneuen_2022_105959 crossref_primary_10_3390_nu12072088 crossref_primary_10_1038_ajg_2013_77 crossref_primary_10_1053_j_gastro_2023_04_031 crossref_primary_10_1111_joim_13282 crossref_primary_10_3390_nu14194117 crossref_primary_10_4103_CJP_CJP_33_20 crossref_primary_10_1016_j_gtc_2017_08_012 crossref_primary_10_1007_s00394_021_02503_5 crossref_primary_10_1007_s11739_023_03343_3 crossref_primary_10_3748_wjg_v22_i32_7186 crossref_primary_10_1038_s41579_025_01163_0 crossref_primary_10_3389_fimmu_2021_761981 crossref_primary_10_1017_S0029665120000026 crossref_primary_10_1080_17512433_2023_2195626 crossref_primary_10_1371_journal_pone_0111717 crossref_primary_10_1007_s40279_024_02167_1 crossref_primary_10_3389_fmed_2025_1435030 crossref_primary_10_1111_jgh_14650 crossref_primary_10_1155_2015_505878 crossref_primary_10_1097_MCO_0b013e3283619e63 crossref_primary_10_1038_ctg_2012_24 crossref_primary_10_20960_nh_03857 crossref_primary_10_3390_nu11010091 crossref_primary_10_1016_j_dld_2023_11_015 crossref_primary_10_3390_nu12113420 crossref_primary_10_3389_fimmu_2023_1321051 crossref_primary_10_1007_s00394_015_0962_6 crossref_primary_10_1111_j_1365_277X_2012_01282_x crossref_primary_10_1111_imcb_12409 crossref_primary_10_1016_j_rdc_2025_01_002 crossref_primary_10_1155_2012_493717 crossref_primary_10_1111_1750_3841_12536 crossref_primary_10_1016_j_tjnut_2023_06_013 crossref_primary_10_2478_aoas_2024_0050 crossref_primary_10_1016_j_sjbs_2022_02_044 crossref_primary_10_3389_fmicb_2023_1188455 crossref_primary_10_3390_ijms17040578 crossref_primary_10_3390_nu11051033 crossref_primary_10_1111_1751_2980_12422 crossref_primary_10_1186_s40168_023_01520_2 crossref_primary_10_1111_imj_15520 crossref_primary_10_3389_fnagi_2017_00403 crossref_primary_10_1093_advances_nmz004 crossref_primary_10_3390_jcm10112466 crossref_primary_10_3389_fnut_2022_931458 crossref_primary_10_3389_fimmu_2018_02240 crossref_primary_10_3390_nu5061869 crossref_primary_10_5217_ir_2023_00080 crossref_primary_10_1007_s11894_018_0667_0 crossref_primary_10_1016_j_gtc_2017_05_004 crossref_primary_10_3389_fimmu_2022_866059 crossref_primary_10_3390_immuno4040026 crossref_primary_10_1111_1541_4337_12119 crossref_primary_10_1007_s11926_018_0758_9 crossref_primary_10_1017_S0029665121002846 crossref_primary_10_3390_nu14122423 crossref_primary_10_1093_nutrit_nuae224 crossref_primary_10_3390_biom14101321 crossref_primary_10_1016_j_cimid_2015_10_005 crossref_primary_10_1016_j_clnu_2019_11_002 crossref_primary_10_1093_ecco_jcc_jjz160 crossref_primary_10_1016_j_pharmthera_2014_12_006 crossref_primary_10_1038_ajg_2014_357 crossref_primary_10_1002_ctd2_182 crossref_primary_10_1111_j_1365_2036_2012_05220_x crossref_primary_10_3748_wjg_v23_i14_2483 crossref_primary_10_1097_MD_0000000000003765 crossref_primary_10_3390_nu16234201 crossref_primary_10_1016_j_bcdf_2013_08_001 crossref_primary_10_3390_nu16132092 crossref_primary_10_1093_ecco_jcc_jjv136 crossref_primary_10_1093_ecco_jcc_jjw106 crossref_primary_10_1152_ajpgi_00002_2022 crossref_primary_10_1111_imj_13003 crossref_primary_10_3390_nu12041037 crossref_primary_10_1177_0884533615606898 crossref_primary_10_1093_ecco_jcc_jjz051 crossref_primary_10_1111_apt_15174 crossref_primary_10_1016_j_cgh_2024_05_049 crossref_primary_10_36303_SAPJ_0138 crossref_primary_10_1111_bph_13632 crossref_primary_10_3920_BM2014_0067 crossref_primary_10_1002_jpn3_12134 crossref_primary_10_1053_j_gastro_2022_09_034 crossref_primary_10_1002_ueg2_70011 crossref_primary_10_1097_01_MIB_0000437984_92565_31 crossref_primary_10_1146_annurev_nutr_061121_094908 crossref_primary_10_1586_1744666X_2013_824245 crossref_primary_10_1007_s11930_019_00230_x crossref_primary_10_1007_s00281_017_0658_5 crossref_primary_10_1016_j_jff_2014_04_005 crossref_primary_10_1016_j_gtc_2017_08_004 crossref_primary_10_1016_j_jff_2017_03_001 crossref_primary_10_1016_j_ram_2024_02_002 crossref_primary_10_1053_j_gastro_2015_01_007 crossref_primary_10_1080_17474124_2019_1671822 crossref_primary_10_3945_ajcn_117_156265 crossref_primary_10_12998_wjcc_v8_i6_1013 crossref_primary_10_3390_nu16244349 crossref_primary_10_1016_j_foodres_2023_112980 crossref_primary_10_3390_nu13093208 crossref_primary_10_3389_fnut_2021_718093 crossref_primary_10_1111_jgh_12253 crossref_primary_10_1016_j_cgh_2020_01_046 crossref_primary_10_1093_nutrit_nuab062 crossref_primary_10_1586_17474124_2015_1013031 crossref_primary_10_1016_j_cgh_2018_08_078 crossref_primary_10_2174_1574884715666200312100237 crossref_primary_10_3390_app14052177 crossref_primary_10_1016_j_cellimm_2020_104144 crossref_primary_10_3390_nu12123648 crossref_primary_10_1016_j_bpg_2014_04_001 crossref_primary_10_2174_1871530320666200929140522 crossref_primary_10_3748_wjg_v23_i47_8321 crossref_primary_10_1017_S0029665114001153 crossref_primary_10_1016_j_freeradbiomed_2013_11_008 crossref_primary_10_1038_s41598_019_41837_3 crossref_primary_10_3390_nu14234965 crossref_primary_10_1136_archdischild_2020_320875 crossref_primary_10_3390_nu12051423 crossref_primary_10_3390_biomedicines10061242 crossref_primary_10_1016_j_cgh_2015_12_029 crossref_primary_10_1111_apt_15818 crossref_primary_10_3390_nu13051533 crossref_primary_10_1007_s11938_014_0042_7 crossref_primary_10_31146_1682_8658_ecg_190_6_57_62 crossref_primary_10_1111_nmo_13675 crossref_primary_10_3945_jn_112_158147 crossref_primary_10_1002_mnfr_201100630 crossref_primary_10_1093_ecco_jcc_jjx073 crossref_primary_10_17116_dokgastro2018703118 crossref_primary_10_1097_SGA_0b013e3182a67a9a crossref_primary_10_3945_jn_113_185249 crossref_primary_10_1136_gutjnl_2015_309990 crossref_primary_10_1111_jgh_16795 crossref_primary_10_1017_S0029665114000639 crossref_primary_10_3390_nu13051628 crossref_primary_10_3390_nu16060778 crossref_primary_10_3390_biom11121903 crossref_primary_10_1016_j_clnu_2016_12_027 crossref_primary_10_3390_nu10111783 crossref_primary_10_3390_nu13103598 crossref_primary_10_3390_nu10020172 crossref_primary_10_1016_j_fct_2023_114009 crossref_primary_10_3389_fimmu_2018_03183 crossref_primary_10_1080_19490976_2018_1526583 crossref_primary_10_3390_nu12123751 crossref_primary_10_1007_s12602_023_10075_5 crossref_primary_10_3345_cep_2019_00500 crossref_primary_10_1016_j_clnu_2021_05_033 crossref_primary_10_1016_j_bpg_2016_02_002 crossref_primary_10_1016_j_medmic_2022_100070 crossref_primary_10_1111_jhn_13054 crossref_primary_10_1002_ppul_26913 crossref_primary_10_3390_metabo12080720 crossref_primary_10_3389_fmed_2014_00023 crossref_primary_10_1016_j_carbpol_2021_119043 crossref_primary_10_1016_j_foodres_2020_109796 crossref_primary_10_1016_j_clnu_2022_12_004 crossref_primary_10_1053_j_gastro_2016_10_019 crossref_primary_10_1111_jgh_13700 crossref_primary_10_1016_j_foodhyd_2023_108495 crossref_primary_10_1007_s40137_018_0214_9 crossref_primary_10_1093_jbmrpl_ziae021 crossref_primary_10_1039_D1FO01147B crossref_primary_10_1080_10408398_2022_2098246 |
| ContentType | Journal Article |
| Copyright | 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. 2015 INIST-CNRS 2011 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. |
| Copyright_xml | – notice: 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. – notice: 2015 INIST-CNRS – notice: 2011 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7T5 H94 7X8 ADTOC UNPAY |
| DOI | 10.1136/gut.2010.232025 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection BMJ Journals ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Central Student AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-3288 |
| EndPage | 929 |
| ExternalDocumentID | oai:qmro.qmul.ac.uk:123456789/15338 4014322431 21262918 24228456 10_1136_gut_2010_232025 ark_67375_NVC_B3Z31WG3_6 gutjnl |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ .VT 08G 0R~ 18M 29I 2WC 354 39C 3O- 4.4 40O 53G 5GY 5VS 7X7 7~S 88E 88I 8AF 8F7 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAUVZ AAWJN AAYEP ABAAH ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACQHZ ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AENEX AERUA AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AI. AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 DWQXO E3Z EBS EJD F5P FD8 FEDTE FYUFA GNUQQ GX1 H13 HAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IEA IH2 IHR INH INR IOF ITC J5H KQ8 L7B LK8 M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZM PHGZT PMFND PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UKHRP UYXKK V24 VH1 VM9 VVN W8F WH7 WOQ X7M YFH YOC YQY ZGI ZXP ZY1 3V. ABJNI BSCLL RHF AAYXX ADGHP CITATION PJZUB PPXIY PQGLB PUEGO IQODW CGR CUY CVF ECM EIF NPM PKN 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7T5 H94 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-b537t-ba2338e5bf4d819d482d27db689f894dbd31338fdbc31798b5a35f6abad3c80a3 |
| IEDL.DBID | 7X7 |
| ISSN | 0017-5749 1468-3288 |
| IngestDate | Tue Aug 19 21:50:39 EDT 2025 Wed Oct 01 14:13:28 EDT 2025 Fri Sep 05 06:23:12 EDT 2025 Fri Jul 25 09:44:06 EDT 2025 Wed Feb 19 01:50:03 EST 2025 Mon Jul 21 09:12:16 EDT 2025 Wed Oct 01 04:16:09 EDT 2025 Thu Apr 24 22:56:40 EDT 2025 Wed Oct 30 09:48:04 EDT 2024 Thu Apr 24 23:05:33 EDT 2025 Mon Jun 09 14:20:16 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Crohn disease Digestive diseases Intestinal disease Gastroenterology Inflammatory disease |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b537t-ba2338e5bf4d819d482d27db689f894dbd31338fdbc31798b5a35f6abad3c80a3 |
| Notes | local:gutjnl;60/7/923 href:gutjnl-60-923.pdf Related-article-href:10.1136/gut.2010.234369 ArticleID:gutjnl232025 See Commentary, p 882 related-article-ID:RA1 PMID:21262918 ark:/67375/NVC-B3Z31WG3-6 istex:0243E3A67A60AF0D9F495830D20A97C0BE24A87E ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://qmro.qmul.ac.uk/xmlui/bitstream/123456789/15338/1/McCarthy%20Randomised%2c%20double-blind%2c%20placebo-controlled%202011%20Published.pdf |
| PMID | 21262918 |
| PQID | 1779350408 |
| PQPubID | 2041069 |
| PageCount | 7 |
| ParticipantIDs | unpaywall_primary_10_1136_gut_2010_232025 proquest_miscellaneous_871000670 proquest_miscellaneous_1753460345 proquest_journals_1779350408 pubmed_primary_21262918 pascalfrancis_primary_24228456 crossref_citationtrail_10_1136_gut_2010_232025 crossref_primary_10_1136_gut_2010_232025 istex_primary_ark_67375_NVC_B3Z31WG3_6 bmj_primary_10_1136_gut_2010_232025 bmj_journals_10_1136_gut_2010_232025 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-07-01 |
| PublicationDateYYYYMMDD | 2011-07-01 |
| PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Gut |
| PublicationTitleAbbrev | Gut |
| PublicationTitleAlternate | Gut |
| PublicationYear | 2011 |
| Publisher | BMJ Publishing Group Ltd and British Society of Gastroenterology BMJ Publishing Group BMJ Publishing Group LTD |
| Publisher_xml | – name: BMJ Publishing Group Ltd and British Society of Gastroenterology – name: BMJ Publishing Group – name: BMJ Publishing Group LTD |
| References | Cherbut, Michel, Lecannu (b22) 2003; 133 Leenen, Dieleman (b16) 2007; 137 Sokol, Seksik, Furet (b11) 2009; 15 Millard, Mertes, Ittelet (b21) 2002; 130 Ng, Plamondon, Kamm (b36) 2010; 16 Sartor (b3) 2008; 134 Barrett, Gearry, Muir (b32) 2010; 31 Marteau, Sokol, Dray (b15) 2009; 33 Gearry, Irving, Barrett (b31) 2009; 3 Ivanov, Frutos, Manel (b1) 2008; 4 Stagg, Hart, Knight (b5) 2003; 52 Hart, Lammers, Brigidi (b6) 2004; 53 Kolida, Meyer, Gibson (b34) 2007; 61 van Loo, Coussement, de Leenheer (b17) 1995; 35 Lindsay, Whelan, Stagg (b23) 2006; 55 Suau, Rochet, Sghir (b27) 2001; 24 Ramirez-Farias, Slezak, Fuller (b19) 2009; 101 Mylonaki, Rayment, Rampton (b8) 2005; 11 Tamboli, Neut, Desreumaux (b10) 2004; 53 Bell, Rigby, English (b25) 2001; 166 Swidsinski, Ladhoff, Pernthaler (b9) 2002; 122 Whelan, Judd, Preedy (b29) 2005; 135 Marteau, Lemann, Seksik (b12) 2006; 55 Rolfe, Fortun, Hawkey (b13) 2006 Langendijk, Schut, Jansen (b26) 1995; 61 Ng, Kamm, Stagg (b35) 2010; 16 Gibson, Beatty, Wang (b18) 1995; 108 Probert, Apajalahti, Rautonen (b37) 2004; 70 Pedersen, Sandstrom, Van Amelsvoort (b24) 1997; 78 Gibson, Shepherd (b38) 2005; 21 Sokol, Pigneur, Watterlot (b7) 2008; 105 Rescigno, Urbano, Valzasina (b4) 2001; 2 Pasare, Medzhitov (b28) 2003; 299 Hedin, Mullard, Sharratt (b33) 2010; 16 Hedin, Whelan, Lindsay (b14) 2007; 66 Wang, Gibson (b20) 1993; 75 Su, Lichtenstein, Krok (b30) 2004; 126 Rakoff-Nahoum, Paglino, Eslami-Varzaneh (b2) 2004; 118 Probert, Apajalahti, Rautonen 2004; 70 Barrett, Gearry, Muir 2010; 31 Langendijk, Schut, Jansen 1995; 61 Swidsinski, Ladhoff, Pernthaler 2002; 122 Pedersen, Sandstrom, Van Amelsvoort 1997; 78 Suau, Rochet, Sghir 2001; 24 Rakoff-Nahoum, Paglino, Eslami-Varzaneh 2004; 118 Stagg, Hart, Knight 2003; 52 Hart, Lammers, Brigidi 2004; 53 Ramirez-Farias, Slezak, Fuller 2009; 101 Rescigno, Urbano, Valzasina 2001; 2 Hedin, Mullard, Sharratt 2010; 16 Cherbut, Michel, Lecannu 2003; 133 Sokol, Seksik, Furet 2009; 15 Gibson, Beatty, Wang 1995; 108 Ng, Plamondon, Kamm 2010; 16 Sokol, Pigneur, Watterlot 2008; 105 Wang, Gibson 1993; 75 Su, Lichtenstein, Krok 2004; 126 Marteau, Lemann, Seksik 2006; 55 Millard, Mertes, Ittelet 2002; 130 Pasare, Medzhitov 2003; 299 Ivanov, Frutos, Manel 2008; 4 Sartor 2008; 134 Gearry, Irving, Barrett 2009; 3 Rolfe, Fortun, Hawkey 2006 Hedin, Whelan, Lindsay 2007; 66 Lindsay, Whelan, Stagg 2006; 55 Tamboli, Neut, Desreumaux 2004; 53 van Loo, Coussement, de Leenheer 1995; 35 Mylonaki, Rayment, Rampton 2005; 11 Leenen, Dieleman 2007; 137 Gibson, Shepherd 2005; 21 Marteau, Sokol, Dray 2009; 33 Ng, Kamm, Stagg 2010; 16 Whelan, Judd, Preedy 2005; 135 Bell, Rigby, English 2001; 166 Kolida, Meyer, Gibson 2007; 61 21749983 - Gut. 2012 Jun;61(6):958 21618354 - Inflamm Bowel Dis. 2012 Feb;18(2):391-2 21436225 - Gut. 2011 Jul;60(7):882-3 |
| References_xml | – volume: 299 start-page: 1033 year: 2003 ident: b28 article-title: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells publication-title: Science – volume: 66 start-page: 307 year: 2007 ident: b14 article-title: Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials publication-title: Proc Nutr Soc – volume: 24 start-page: 139 year: 2001 ident: b27 article-title: Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora publication-title: Syst Appl Microbiol – volume: 108 start-page: 975 year: 1995 ident: b18 article-title: Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin publication-title: Gastroenterology – volume: 126 start-page: 1257 year: 2004 ident: b30 article-title: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease publication-title: Gastroenterology – volume: 31 start-page: 874 year: 2010 ident: b32 article-title: Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon publication-title: Aliment Pharmacol Ther – volume: 4 start-page: 337 year: 2008 ident: b1 article-title: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine publication-title: Cell Host Microbe – volume: 75 start-page: 373 year: 1993 ident: b20 article-title: Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine publication-title: J Appl Bacteriol – volume: 133 start-page: 21 year: 2003 ident: b22 article-title: The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats publication-title: J Nutr – volume: 137 start-page: 2572S year: 2007 ident: b16 article-title: Inulin and oligofructose in chronic inflammatory bowel disease publication-title: J Nutr – volume: 53 start-page: 1602 year: 2004 ident: b6 article-title: Modulation of human dendritic cell phenotype and function by probiotic bacteria publication-title: Gut – volume: 52 start-page: 1522 year: 2003 ident: b5 article-title: The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria publication-title: Gut – volume: 118 start-page: 229 year: 2004 ident: b2 article-title: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis publication-title: Cell – volume: 134 start-page: 577 year: 2008 ident: b3 article-title: Microbial influences in inflammatory bowel diseases publication-title: Gastroenterology – volume: 101 start-page: 541 year: 2009 ident: b19 article-title: Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii publication-title: Br J Nutr – volume: 53 start-page: 1 year: 2004 ident: b10 article-title: Dysbiosis in inflammatory bowel disease publication-title: Gut – volume: 55 start-page: 348 year: 2006 ident: b23 article-title: Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease publication-title: Gut – volume: 21 start-page: 1399 year: 2005 ident: b38 article-title: Personal view: food for thought—Western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis publication-title: Aliment Pharmacol Ther – volume: 35 start-page: 525 year: 1995 ident: b17 article-title: On the presence of inulin and oligofructose as natural ingredients in the western diet publication-title: Crit Rev Food Sci Nutr – volume: 78 start-page: 215 year: 1997 ident: b24 article-title: The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females publication-title: Br J Nutr – volume: 15 start-page: 1183 year: 2009 ident: b11 article-title: Low counts of Faecalibacterium prausnitzii in colitis microbiota publication-title: Inflamm Bowel Dis – volume: 105 start-page: 16731 year: 2008 ident: b7 article-title: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients publication-title: Proc Natl Acad Sci U S A – volume: 16 start-page: 2099 year: 2010 ident: b33 article-title: Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study publication-title: Inflamm Bowel Dis – volume: 2 start-page: 361 year: 2001 ident: b4 article-title: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria publication-title: Nat Immunol – volume: 55 start-page: 842 year: 2006 ident: b12 article-title: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial publication-title: Gut – volume: 166 start-page: 4958 year: 2001 ident: b25 article-title: Migration and maturation of human colonic dendritic cells publication-title: J Immunol – start-page: CD004826 issue: 4 year: 2006 ident: b13 article-title: Probiotics for maintenance of remission in Crohn's disease publication-title: Cochrane Database Syst Rev – volume: 3 start-page: 8 year: 2009 ident: b31 article-title: Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study publication-title: J Crohns Colitis – volume: 130 start-page: 245 year: 2002 ident: b21 article-title: Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages publication-title: Clin Exp Immunol – volume: 61 start-page: 1189 year: 2007 ident: b34 article-title: A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans publication-title: Eur J Clin Nutr – volume: 16 start-page: 1286 year: 2010 ident: b36 article-title: Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis publication-title: Inflamm Bowel Dis – volume: 11 start-page: 481 year: 2005 ident: b8 article-title: Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease publication-title: Inflamm Bowel Dis – volume: 70 start-page: 4505 year: 2004 ident: b37 article-title: Polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system publication-title: Appl Environ Microbiol – volume: 61 start-page: 3069 year: 1995 ident: b26 article-title: Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples publication-title: Appl Environ Microbiol – volume: 135 start-page: 1896 year: 2005 ident: b29 article-title: Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans publication-title: J Nutr – volume: 16 start-page: 1787 year: 2010 ident: b35 article-title: Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation publication-title: Inflamm Bowel Dis – volume: 122 start-page: 44 year: 2002 ident: b9 article-title: Mucosal flora in inflammatory bowel disease publication-title: Gastroenterology – volume: 33 start-page: S228 year: 2009 ident: b15 article-title: Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? publication-title: Gastroenterol Clin Biol – volume: 133 start-page: 21 year: 2003 article-title: The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats publication-title: J Nutr – volume: 126 start-page: 1257 year: 2004 article-title: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease publication-title: Gastroenterology – volume: 299 start-page: 1033 year: 2003 article-title: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells publication-title: Science – volume: 52 start-page: 1522 year: 2003 article-title: The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria publication-title: Gut – volume: 53 start-page: 1 year: 2004 article-title: Dysbiosis in inflammatory bowel disease publication-title: Gut – volume: 134 start-page: 577 year: 2008 article-title: Microbial influences in inflammatory bowel diseases publication-title: Gastroenterology – volume: 61 start-page: 3069 year: 1995 article-title: Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples publication-title: Appl Environ Microbiol – volume: 24 start-page: 139 year: 2001 article-title: Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora publication-title: Syst Appl Microbiol – volume: 15 start-page: 1183 year: 2009 article-title: Low counts of Faecalibacterium prausnitzii in colitis microbiota publication-title: Inflamm Bowel Dis – volume: 135 start-page: 1896 year: 2005 article-title: Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans publication-title: J Nutr – volume: 35 start-page: 525 year: 1995 article-title: On the presence of inulin and oligofructose as natural ingredients in the western diet publication-title: Crit Rev Food Sci Nutr – volume: 31 start-page: 874 year: 2010 article-title: Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon publication-title: Aliment Pharmacol Ther – volume: 4 start-page: 337 year: 2008 article-title: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine publication-title: Cell Host Microbe – volume: 2 start-page: 361 year: 2001 article-title: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria publication-title: Nat Immunol – volume: 75 start-page: 373 year: 1993 article-title: Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine publication-title: J Appl Bacteriol – volume: 33 start-page: S228 year: 2009 article-title: Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? publication-title: Gastroenterol Clin Biol – volume: 11 start-page: 481 year: 2005 article-title: Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease publication-title: Inflamm Bowel Dis – volume: 118 start-page: 229 year: 2004 article-title: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis publication-title: Cell – volume: 105 start-page: 16731 year: 2008 article-title: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients publication-title: Proc Natl Acad Sci U S A – volume: 55 start-page: 348 year: 2006 article-title: Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease publication-title: Gut – volume: 3 start-page: 8 year: 2009 article-title: Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study publication-title: J Crohns Colitis – volume: 16 start-page: 2099 year: 2010 article-title: Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study publication-title: Inflamm Bowel Dis – volume: 101 start-page: 541 year: 2009 article-title: Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii publication-title: Br J Nutr – volume: 61 start-page: 1189 year: 2007 article-title: A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans publication-title: Eur J Clin Nutr – volume: 166 start-page: 4958 year: 2001 article-title: Migration and maturation of human colonic dendritic cells publication-title: J Immunol – volume: 66 start-page: 307 year: 2007 article-title: Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials publication-title: Proc Nutr Soc – volume: 21 start-page: 1399 year: 2005 article-title: Personal view: food for thought—Western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis publication-title: Aliment Pharmacol Ther – volume: 108 start-page: 975 year: 1995 article-title: Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin publication-title: Gastroenterology – volume: 16 start-page: 1787 year: 2010 article-title: Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation publication-title: Inflamm Bowel Dis – volume: 78 start-page: 215 year: 1997 article-title: The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females publication-title: Br J Nutr – volume: 16 start-page: 1286 year: 2010 article-title: Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis publication-title: Inflamm Bowel Dis – volume: 137 start-page: 2572S year: 2007 article-title: Inulin and oligofructose in chronic inflammatory bowel disease publication-title: J Nutr – volume: 53 start-page: 1602 year: 2004 article-title: Modulation of human dendritic cell phenotype and function by probiotic bacteria publication-title: Gut – volume: 122 start-page: 44 year: 2002 article-title: Mucosal flora in inflammatory bowel disease publication-title: Gastroenterology – volume: 55 start-page: 842 year: 2006 article-title: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial publication-title: Gut – start-page: CD004826 issue: 4 year: 2006 article-title: Probiotics for maintenance of remission in Crohn's disease publication-title: Cochrane Database Syst Rev – volume: 130 start-page: 245 year: 2002 article-title: Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages publication-title: Clin Exp Immunol – volume: 70 start-page: 4505 year: 2004 article-title: Polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system publication-title: Appl Environ Microbiol – reference: 21749983 - Gut. 2012 Jun;61(6):958 – reference: 21436225 - Gut. 2011 Jul;60(7):882-3 – reference: 21618354 - Inflamm Bowel Dis. 2012 Feb;18(2):391-2 |
| SSID | ssj0008891 |
| Score | 2.5057578 |
| Snippet | IntroductionThe commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and... Introduction The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and... The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium... INTRODUCTION: The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and... |
| SourceID | unpaywall proquest pubmed pascalfrancis crossref istex bmj |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 923 |
| SubjectTerms | Adult Bifidobacterium - isolation & purification Biological and medical sciences Biomedical research Carbohydrates clinical trials Crohn Disease - drug therapy Crohn Disease - immunology Crohn Disease - microbiology Crohn's disease Cytokines Dendritic cells Dendritic Cells - immunology Double-Blind Method Endoscopy Faecalibacterium prausnitzii Feces - microbiology Female Fermentation Fructo-oligosaccharide Gastroenterology. Liver. Pancreas. Abdomen Humans Immunity, Mucosal Immunology Inflammation Inflammatory bowel disease Intestinal Mucosa - immunology inulin Male Medical sciences Medication Adherence Middle Aged molecular immunology oligofructose Oligosaccharides - adverse effects Oligosaccharides - therapeutic use Other diseases. Semiology prebiotic Prebiotics Prebiotics - adverse effects Probiotics Rectum - immunology Rodents Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Studies Treatment Outcome University colleges |
| Title | Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease |
| URI | https://gut.bmj.com/content/60/7/923.full http://gut.bmj.com/content/60/7/923.full https://api.istex.fr/ark:/67375/NVC-B3Z31WG3-6/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/21262918 https://www.proquest.com/docview/1779350408 https://www.proquest.com/docview/1753460345 https://www.proquest.com/docview/871000670 https://qmro.qmul.ac.uk/xmlui/bitstream/123456789/15338/1/McCarthy%20Randomised%2c%20double-blind%2c%20placebo-controlled%202011%20Published.pdf |
| UnpaywallVersion | submittedVersion |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-3288 dateEnd: 20250401 omitProxy: true ssIdentifier: ssj0008891 issn: 0017-5749 databaseCode: 7X7 dateStart: 19600301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1468-3288 dateEnd: 20250401 omitProxy: true ssIdentifier: ssj0008891 issn: 0017-5749 databaseCode: BENPR dateStart: 19600301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Zb9QwELagK3E8IG4CZRUE4pAITeIj2SdEVy0VUleoorDqS2THzrYljZfNRsC_ZybxhlZi6WOUcQ7PF_sb-8sMIS-UCFmSiCKQeR4GjJkokKPQBCrRQgCbK7qMN_sTsXfIPk351C241U5WuRoT24Fa2xzXyLeiBJDEAXLp-_mPAKtG4e6qK6FxlQwioCqI6mTaB1yo4IlWIzFP2Mil9omo2Jo1y07XFWMBcZxZ1NnphblpgN38C7WSsobuKro6F_8iojfJ9aaay98_ZVmem5x2b5NbjlX6HzoY3CFXTHWXXNt3--b3yOxAVtqCS41-62vbqBL6CQgmHLWiLGUDp1kvjfbbSh6-LfwCc8vawJYnM1tDNx9DYK1N7Z9UvmzHSX-8sMfVq9p3-zz3yeHuzpfxXuBKLASK02QZKBlDjGo4yvWAG2iWxjpOtBLpqEhHTCtNMYgttMoppjZTXFJeCKmkpnkaSvqAbFS2Mo-IzwpgYoomOdeUGWikuApzwaVUEJaEoQfAODvN3CdSZ230QUUGnsjQE1nnCY88R7N5l2tjvdW7laey3CUzx5oa5foGr_sGl177Zev63k4uvqP8LeHZ5Os426ZHNPr2kWbCI8ML2OgbxJhXDZipRzZXYDn33j2QPfKsPw0IwJ0aWRnboA2nTISUwcP4a2xSzMuEf1l55GGHw7_3j2IRjyK4wZsemJe99eP_P-sTcqNbTUeh8ibZWC4a8xTo2FIN229uSAbbO5PPB38Ag2Iugw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKK1F4QNwESjHilghN4iPZB4RgoWxpuw-ohRUvwY6dbUuaLHuo9E_xG5nJRSux9KmPUca5vs_2jP1lhpDHWno8DGXqqiTxXM6t76qOZ10dGinBm0urjDfbfdnb5Z8GYrBAfjf_wqCsshkTy4HaFAmuka_5ITBJAOWiN6OfLlaNwt3VpoRGRYtNe3wEIdvk9cZ7wPdJEKx_2On23LqqgKsFC6euVgGEZVagQg2mQ8OjwASh0TLqpFGHG20Yxm2p0QnDbF5aKCZSqbQyLIk8xeC6F8gSZx7HXP3hoA3wUDHkNyO_CHmnTiXkM7k2nE0rHVmABctxJtOHB6fmwiWE9RdqM9UE4Emruhr_cnwvk-VZPlLHRyrLTkyG61fJldqLpW8r2l0jCza_Ti5u1_v0N8jws8pNARSy5iU1xUxngAs4tHBUisB04dYa-cwaWlYOoUVKU8xlW7hFtj8sJgDrHgTyxk7ofk5VOS7T7rjYy59NaL2vdJPsnsvHv0UW8yK3dwjlKXh-moWJMIxbaKSF9hIplNIQBnmeA0Q8PIjrLjmJy2iHyRiQiBGJuELCIY_QbFTl9phv9apBKk7q5OlYwyOb3-B52-DMaz8toW_t1PgHyu1CEfe_dON37Bvzv35ksXTI6ilutA0CzOMGnrBDVhqynHjvtuM45GF7GhiAO0Mqt8UMbQTj0mMcHobOsYkwDxT-1eWQ2xUP_97fD2TQ8eEGL1pinvXWd___rA_Icm9neyve2uhv3iOXqpV8FEmvkMXpeGbvgys41atl_6Pk-3l3-D_pWGrF |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVirwgLhjKGURdwkT23tx8oAQpJSW0gghChEvZte7TltcO8SJSn-Nr2PGN1qJ0Kc-Rtn17ZzZmfEezxDyUEuPh6FMXBXHnsu59V3V86yrQyMlRHNJVfFmeyA3dvj7oRgukN_NtzAoq2zWxHKhNnmM78g7fghMEkC5biepZREf19ZfjX-62EEKd1qbdhoVRbbs0SGkb8XLzTXA-lEQrL_93N9w6w4DrhYsnLpaBZCiWYFqNXCNhncDE4RGy24v6fa40YZhDpcYHTOs7KWFYiKRSivD4q6nGBz3HFkKGWcoJwuHbbKH6iG_8QIi5L26rJDPZGc0m1aasgCbl6NX0wf7J_ziEkL8C3WaqgCokqrHxr-C4Ivk_Cwbq6NDlabHHOP6ZXKpjmjp64qCV8iCza6S5e16z_4aGX1SmcmBTtY8pyaf6RQwguAWfpWCMJ27tV4-tYaWXURontAE69rmbp7ujfICIN6FpN7Ygu5lVJVrNO1P8t3sSUHrPabrZOdMHv4Nspjlmb1FKE8gCtQsjIVh3MIkLbQXS6GUhpTI8xwg5cF-VJtnEZWZD5MRIBEhElGFhEMe4LBxVedj_qgXDVJRXBdSx34e6fwJT9sJpx77cQl9O05NfqD0LhTR4Es_esO-Mf_rOxZJh6ye4EY7IcCabhAVO2SlIcux-26NyCH327-BAbhLpDKbz3CMYFx6jMPF0DljulgTCr_wcsjNiod_z-8HMuj5cIJnLTFPu-vb_7_We2QZTD36sDnYukMuVC_1US-9Qhank5m9C1HhVK-W5kfJ97O29z9DlG8A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomised%2C+double-blind%2C+placebo-controlled+trial+of+fructo-oligosaccharides+in+active+Crohn%27s+disease&rft.jtitle=Gut&rft.au=Benjamin%2C+Jane+L&rft.au=Hedin%2C+Charlotte+R+H&rft.au=Koutsoumpas%2C+Andreas&rft.au=Ng%2C+Siew+C&rft.date=2011-07-01&rft.issn=0017-5749&rft.volume=60&rft.issue=7&rft.spage=923&rft.epage=929&rft_id=info:doi/10.1136%2Fgut.2010.232025&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-5749&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-5749&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-5749&client=summon |